Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Immunovant, Inc. - Common Stock (NQ:IMVT)

26.19 +0.13 (+0.49%)

Streaming Delayed Price Updated: 11:56 AM EST, Jan 29, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	199,328
Open	25.92
Bid (Size)	26.16 (100)
Ask (Size)	26.21 (200)
Prev. Close	26.06
Today's Range	25.76 - 26.40
52wk Range	12.72 - 27.80
Shares Outstanding	114,998,871
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? ↗

December 18, 2025

Focused on monoclonal antibody therapies for autoimmune diseases, this biotech just reported a significant insider buy in public filings.

Via The Motley Fool

Immunovant Inc (NASDAQ:IMVT) Stock Falls 10% on Q2 FY2026 Earnings and Corporate Updates ↗

November 10, 2025

Immunovant stock drops 10% despite meeting Q2 FY2026 earnings estimates. The sell-off is driven by investor reaction to clinical pipeline updates for its anti-FcRn therapies.

Via Chartmill

Performance

YTD	+1.1%	+1.1%
1 Month	+2.3%	+2.3%
3 Month	+21.0%	+21.0%
6 Month	+57.6%	+57.6%
1 Year	+18.9%	+18.9%

More News

Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

November 10, 2025

Via Benzinga

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

Insights into Immunovant's Upcoming Earnings ↗

November 07, 2025

Via Benzinga

Cardinal Health Posts Upbeat Q1 Results, Joins Guardant Health, Glaukos, C.H. Robinson And Other Big Stocks Moving Higher On Thursday ↗

October 30, 2025

Via Benzinga

IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

September 17, 2025

From Kahn Swick & Foti, LLC

Via GlobeNewswire

IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

September 12, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

Why Immunovant Stock Blasted Higher Today ↗

September 03, 2025

Via The Motley Fool

IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm

August 27, 2025

From The Schall Law Firm

Via Business Wire

IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

August 13, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

Immunovant Posts 34% R&D Jump in Q1 ↗

August 11, 2025

Via The Motley Fool

IMVT INVESTIGATION ALERT: Pittsburgh Law Office of Alfred G. Yates Jr. PC Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm

June 20, 2025

Via ACCESS Newswire

Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence ↗

May 29, 2025

Via Stocktwits

IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm

May 21, 2025

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

Charles Schwab To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

April 22, 2025

Via Benzinga

Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift ↗

April 21, 2025

Via Investor's Business Daily

Immunovant Announces Roivant President Eric Venker As New CEO: Retail’s Elated ↗

April 21, 2025

Via Stocktwits

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

April 21, 2025

From Roivant Sciences

Via GlobeNewswire

Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data ↗

March 19, 2025

Via Benzinga

Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled. ↗

March 19, 2025

Via Investor's Business Daily

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 19, 2025

Via Benzinga

Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity ↗

March 04, 2025

Via Investor's Business Daily

High Frequency Trading, PPI Misreads Helped Fuel a Short Squeeze... Now What ↗

January 19, 2025

Via Talk Markets

Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases ↗

September 25, 2024

Via Investor's Business Daily

Frequently Asked Questions

Is Immunovant, Inc. - Common Stock publicly traded?

Yes, Immunovant, Inc. - Common Stock is publicly traded.

What exchange does Immunovant, Inc. - Common Stock trade on?

Immunovant, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Immunovant, Inc. - Common Stock?

The ticker symbol for Immunovant, Inc. - Common Stock is IMVT on the Nasdaq Stock Market

What is the current price of Immunovant, Inc. - Common Stock?

The current price of Immunovant, Inc. - Common Stock is 26.19

When was Immunovant, Inc. - Common Stock last traded?

The last trade of Immunovant, Inc. - Common Stock was at 01/29/26 11:56 AM ET

What is the market capitalization of Immunovant, Inc. - Common Stock?

The market capitalization of Immunovant, Inc. - Common Stock is 3.01B

How many shares of Immunovant, Inc. - Common Stock are outstanding?

Immunovant, Inc. - Common Stock has 3B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.